Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.
Generation and Characterization of Fully Human Monoclonal Antibodies Against Human Orai1 for Autoimmune Disease.
Predictive value of early brain atrophy on response in patients treated with interferon β.
Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination.
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.
Pediatric multiple sclerosis.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Multiple sclerosis.
Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.
Neuroprotective effects of recombinant T-cell receptor ligand in autoimmune optic neuritis in HLA-DR2 mice.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
[Intractable vomiting as first manifestation of neuromyelitis Optica.]
Microglia activation is associated with IFN-α induced depressive-like behavior.
Drak2 Does Not Regulate TGF-β Signaling in T Cells.
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.
Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
Genzyme's Lemtrada resubmission accepted for review by FDA
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Epidemiology of Neuromyelitis Optica in the United States: A Multicenter AnalysisEpidemiology of NMO.
Disease-modifying treatments for progressive multiple sclerosis.
Glatiramer acetate does not protect from acute ischemic stroke in mice.

Pages